New cancer drug targets stomach and pancreatic tumors in early trial
NCT ID NCT04632108
Summary
This early-stage study is testing a new drug called ASKB589 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, see how the body processes the drug, and check if it can shrink tumors, especially in stomach and pancreatic cancers. The study is for adults who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing cancer hospital
Beijing, Beijing Municipality, 100089, China
-
Linyi cancer hospital
Linyi, Shandong, 276000, China
Conditions
Explore the condition pages connected to this study.